SORAFENIB (FREE BASE)

Background Information:

An inhibitor of Raf kinase, Platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF) receptor 2 & 3 kinases.

Reference:

1. Davies JM, Dhruva NS, Walko CM, Socinski MA, Bernard S, Hayes DN,
Kim WY, Ivanova A, Keller K, Hilbun LR, Chiu M, Dees EC, Stinchcombe TE.
A phase I trial of sorafenib combined with cisplatin/etoposide or
carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer.
2010 Jun 24. [Epub ahead of print] PubMed PMID: 20580118.
2. Haubeiss S, Schmid JO, Muerdter TE, Sonnenberg M, Friedel G, van der
Kuip H, Aulitzky WE. Dasatinib reverses Cancer-associated Fibroblasts
(CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of
normal Fibroblasts. Mol Cancer. 2010 Jun 27;9(1):168. [Epub ahead of
print] PubMed PMID: 20579391.
3. Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: Where do we go
from here? Hepatology. 2010 Mar 1;52(1):360-369. [Epub ahead of print]
PubMed PMID: 20578152.

APIM050241: SORAFENIB (FREE BASE)

CAS No.: 284461-73-0.
Molecular Formula: C₂₁H₁₆ClF₃N₄O_3.
Molecular Weight: 464.8.
Purity: > 99% (HPLC).
QC: ¹HNMR, HPLC, and Quantitative Elemental Anlysis
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.